ChromaDex to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022
August 02 2022 - 6:32AM
Business Wire
ChromaDex Corp. (NASDAQ:CDXC) announced that it will hold a
conference call on Wed. August 10, 2022 at 4:30 p.m. ET to discuss
its financial results for the second quarter, which ended June 30,
2022. The financial results will be reported in a press release
after the close of regular stock market trading hours on the same
day as the conference call.
Investor Conference Call:
ChromaDex management will host an investor conference call to
discuss the second quarter results and provide a general business
update on Wed., August 10, at 4:30 p.m. ET.
Participants should call in at least 10 minutes prior to the
call. The dial-in information is as follows:
Date: Wed., August 10, 2022 Time: 4:30 p.m. ET (1:30 p.m. PT)
Toll-free dial-in number: 1-888-330-2446 Conference ID: 4126168
Webcast link: ChromaDex Second Quarter 2022 Earnings Conference
Call
The conference call will be broadcast live and available for
replay here and via the investor relations section of the Company’s
website at www.chromadex.com.
A replay of the conference call will be available from 7:30 p.m.
ET on August 10, 2022, to 11:59 p.m. ET on August 17, 2022.
Toll-free replay number: 1-800-770-2030 Replay ID: 4126168
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to
healthy aging. The ChromaDex team, which includes world-renowned
scientists, is pioneering research on nicotinamide adenine
dinucleotide (NAD+), levels of which decline with age. ChromaDex is
the innovator behind NAD+ precursor nicotinamide riboside (NR),
commercialized as the flagship ingredient Niagen®. Nicotinamide
riboside and other NAD+ precursors are protected by ChromaDex’s
patent portfolio. ChromaDex maintains a website at
www.chromadex.com to which ChromaDex regularly posts copies of its
press releases as well as additional and financial information
about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities and Exchange Act of 1934. Statements that are
not a description of historical facts constitute forward-looking
statements and may often, but not always, be identified by the use
of such words as “expects,” “anticipates,” “intends,” “estimates,”
“plans,” “potential,” “possible,” “probable,” “believes,” “seeks,”
“may,” “will,” “should,” “could," “predicts,” “projects,”
“continue,” “would” or the negative of such terms or other similar
expressions. More detailed information about ChromaDex and the risk
factors that may affect the realization of forward-looking
statements is set forth in ChromaDex's Annual Report on Form 10-K
for the fiscal year ended December 31, 2021, ChromaDex's Quarterly
Reports on Form 10-Q and other filings submitted by ChromaDex to
the SEC, copies of which may be obtained from the SEC's website at
www.sec.gov. Readers are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
hereof, and actual results may differ materially from those
suggested by these forward-looking statements. All forward-looking
statements are qualified in their entirety by this cautionary
statement and ChromaDex undertakes no obligation to revise or
update this release to reflect events or circumstances after the
date hereof.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220802005139/en/
ChromaDex Investor Relations Contact: Brianna Gerber,
Vice President of Finance and Investor Relations 949-419-0288 ext.
127 briannag@chromadex.com
ChromaDex Media Contact: Kendall Knysch, Director of Media
Relations 310-388-6706 ext. 689 kendall.knysch@chromadex.com
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jun 2024 to Jul 2024
ChromaDex (NASDAQ:CDXC)
Historical Stock Chart
From Jul 2023 to Jul 2024